98 / 144
98
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
Referências
1.
Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular ede-
ma. Ophthalmology. 1983; 90:1301-1317.
2. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-
-derived factor and vascular endothelial growth factor are related to diabetic macular
edema. Ophthalmology. 2006; 113:294-301.
3. Chakravarthy U, Yang Y, Lotery A, et al. Clinical Evidence of the Multifactorial Nature of
Diabetic Macular Edema. Retina. 2017 Mar 13. doi: 10.1097/IAE.0000000000001555.
4. Klein R, Klein B. Vision disorders in diabetes. In: National Diabetes Data Group, ed.
Diabetes in America. 2nd ed.Bethesda, MD: National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases. 1995:293-338.
5. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retino-
pathy. IV. Diabetic macular edema. Ophthalmology. 1984; 91:1464-1474.
6. Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with
type 2 diabetes with or without retinopathy. Mol Vis 2013; 19:1734-1746.
7. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, Nam DH: Changes in aqueous con-
centrations of various cytokines after intravitreal triamcinolone versus bevacizumab for
diabetic macular edema. Am J Ophthalmol 2011; 152: 686-694.
8. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery `uocinolone acetonide vitreous
implants: long-term bene%t in patients with chronic diabetic macular edema. Ophthal-
mology.2014; 121: 1892-1903.
9. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management
of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA).
Ophthalmologica. 2017; 237:185-222.
10. Augustin A. Triple therapy for age-related macular degeneration. Retina (Philadelphia,
Pa.). 2009;29(6 Suppl):S8-11.
11. Kang SW, Park SC, Cho HY, Kang JH. Triple therapy of vitrectomy, intravitreal triamcino-
lone, and macular laser photocoagulation for intractable diabetic macular edema. Am J
Ophthalmol.
2007;144(6):878-885.
12. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and
clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment
Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987; 94: 761-774.
13. Bressler SB, Glassman A, Almukhtar T, et al. Five-Year Outcomes of Ranibizumab With
Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for
Diabetic Macular Edema. Am J Ophthalmol. 2016 Apr; 164: 57-68.
14. Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous
ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA.
2015; 314: 2137-2146.
15. Figueira J, Khan J, Nunes S, et al. Prospective randomized controlled trial comparing
sub-threshold micropulse diode laser photocoagulation and conventional green laser
for clinically signi%cant diabetic macular oedema. Br J Ophthalmol 2009; 93: 1341-
1344.
16. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: Ranibizumab
Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic.Macular
Edema. Ophthalmology. 2011 Apr; 18(4):615-25.
17. Wells JA, Glassman AR, Ayala AR, et al. A`ibercept, bevacizumab, or ranibizumab for